Skip to main content
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease logoLink to Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
. 2026 Aug 30;15(19):e044089. doi: 10.1161/JAHA.125.044089

Transient Increase in Cardiomyocyte Protein O‐GlcNAcylation Enhances Susceptibility to Pressure Overload‐Induced Cardiac Remodeling

Samuel F Chang 1,2,#, Chae‐Myeong Ha 1,#, Manoja K Brahma 1, Luke A Potter 1, Mahima S Reddy 1,2, Sayan Bakshi 1, Kerstin Preuss 1,3, Md Saimoon Rahman 1, Johannes K Fischer 1,3, Caitlin A Harrell 1, Zhihuan Sun 1, John C Chatham 1, Adam R Wende 1,✉
PMCID: PMC13745149  PMID: 42669882

Abstract

Background

The observation that patients with diabetes always under tight‐glycemic control consistently show better cardiovascular disease outcomes compared with patients who transition to tight‐glycemic control after prior conventional glycemic control led to the concept of metabolic memory. Mechanisms such as epigenetics possibly mediate the lasting metabolic memory effects, without a known mechanism. Increased cardiac protein posttranslational O‐linked β‐N‐acetylglucosamine (O‐GlcNAc) modification is implicated in cardiac remodeling observed in diabetes, and our previous work shows that chronically elevated cardiomyocyte O‐GlcNAc causes adverse cardiac changes. We hypothesized that transiently increased cardiomyocyte O‐GlcNAcylation leads to exacerbated adverse cardiac remodeling after subsequent pressure‐overload.

Methods

Using an inducible cardiomyocyte specific, dominant‐negative O‐GlcNAcase (dnOGAh) mouse and single transgenic littermate controls (Con), we induced O‐GlcNAc levels for 2 weeks (ON), followed by a 2‐week washout (OFF); mice then underwent transverse‐aortic constriction (TAC) or Sham surgery followed by comprehensive physiological and molecular assessments.

Results

We observed the expected cardiac remodeling in TAC groups, including decreased cardiac function, and increased hypertrophy and fibrosis. Moreover, these pathologic measures were exacerbated in the ON/OFF‐TAC versus Con‐TAC mice; additionally, transcriptomic analysis of left ventricle tissue from each experimental group showed pathways which supported our fibrosis, hypertrophy and functional results of exacerbated cardiac remodeling, and revealed potential novel molecular pathways underlying this pathologic remodeling.

Conclusions

We observed exacerbated cardiac pathology between ON/OFF‐TAC versus Con‐TAC groups supporting the concept of “O‐GlcNAc memory” as a component of metabolic memory. Moreover, transcriptomic analysis provides insight into potential molecular pathways underpinning this metabolic/O‐GlcNAc memory such as Ccn2/CTGF‐driven fibrosis, and/or Nox4‐driven oxidative stress.

Keywords: cardiac remodeling, diabetic heart disease, metabolic memory, pressure overload, protein O‐GlcNAcylation

Subject Categories: Basic Science Research


graphic file with name JAH3-15-e044089-g002.webp


Nonstandard Abbreviations and Acronyms

DCCT

Diabetes Control and Complications Trial

DEG

differentially expressed genes

dnOGA

dominant‐negative O‐GlcNAcase

EDIC

Epidemiology of Diabetes Interventions and Complications

OGA

O‐GlcNAcase

O‐GlcNAc

O‐linked β‐N‐acetylglucosamine

OGT

O‐GlcNAc transferase

TAC

transverse aortic constriction

Clinical Perspective.

What Is New?

  • We provide a novel paradigm to study phenotypic and molecular effects of specific, transiently increased cardiomyocyte O‐GlcNAcylation on the heart which showed exacerbated adverse cardiac remodeling following pressure‐overload, supporting the concept of O‐GlcNAc memory as a component of metabolic memory.

  • Transcriptomic analysis revealed gene expression changes supporting the observed exacerbated adverse cardiac remodeling (eg, hypertrophy, fibrosis, cardiac dysfunction), as well as identifying potential molecular pathways that could drive cardiac pathology exacerbation of O‐GlcNAc memory.

What Are the Clinical Implications?

  • This study supports a concept of O‐GlcNAc/metabolic memory, where previously increased cardiomyocyte protein O‐GlcNAcylation can impact the later development of differential cardiac pathology—like the pathology seen in metabolic memory research related to the downstream cardiac effects in diabetes and heart failure.

Heart disease is the leading cause of death in the United States 1 and globally. 2 Additionally, prevalence of diabetes is near 10% worldwide, 3 and even higher in the United States 4 ; moreover, among the many health complications, cardiovascular diseases (CVD) are the number 1 cause of death in individuals with diabetes. 5 Advancements in treatments have improved mortality outcomes, however, individuals with diabetes still have significantly increased CVD mortality even after accounting for other risk factors. 6 , 7 , 8 The DCCT (Diabetes Control and Complications Trial) and later EDIC (Epidemiology of Diabetes Interventions and Complications) study found that patients always under tight glycemic control had significantly less major adverse cardiovascular events compared with those initially on conventional therapy (during DCCT) then switched to tight glycemic control (EDIC study) 9 , 10 , 11 , 12 ; this significant benefit has persisted at least 30 years. 13 Results from DCCT/EDIC, along with studies such as the UKDPS (United Kingdom Prospective Diabetes Study) and Veterans Affair Diabetes Trial for type‐2 diabetes, support the concept that previously different levels of glycemic control in diabetic patients could account for the subsequent long‐term differences in cardiovascular outcomes–termed “metabolic memory.” 14 , 15 , 16 , 17 Furthermore, studies have identified epigenetics as possible mechanisms behind metabolic memory's differential outcomes. 18 , 19

It is well known that the diabetes leads to severe perturbations of cardiac metabolism including cellular dysfunction in the context of lipotoxicity, glucotoxicity, and glucolipotoxicity 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ; however, the exact biological mechanisms linking dysregulation of cardiac metabolism and cardiac dysfunction in the diabetes are not well understood. In both diabetic patient hearts and animal models, studies have shown protein post‐translational modifications by O‐linked β‐N‐acetylglucosamine (O‐GlcNAc). 27 , 28 O‐GlcNAcylation occurs when O‐GlcNAc transferase (OGT) adds a single O‐GlcNAc to specific serine/threonine residues 29 ; removal is mediated by O‐GlcNAcase (OGA). 30 O‐GlcNAc plays a variety of roles in physiology and pathology development 31 , 32 , 33 ; specifically in the heart, increased protein O‐GlcNAc post‐ischemia exerts a protective effect, 34 , 35 , 36 while persistently increased cardiac protein O‐GlcNAc can be cardiac maladaptive. 28 , 37 Furthermore, in our recent study using a transgenic mouse model of increased cardiomyocyte protein O‐GlcNAc to evaluate the specific effects of sustained cardiomyocyte O‐GlcNAc on the heart, we found that chronically increased cardiomyocyte protein O‐GlcNAc alone was sufficient to lead to cardiac pathology such as diastolic dysfunction, cardiac hypertrophy, fibrosis, and reduced mitochondrial function, 38 similar to the pathology seen in response to diabetes.

The mechanism of metabolic memory under hyperglycemic conditions has been proven to change epigenetics through alterations in chromatin structure. Particularly, transiently high glucose induces persistent histone H3 lysine 4 monomethylation (H3K4me1) at inflammatory gene promoters, providing evidence of hyperglycemic memory. 39 , 40 , 41 In addition to these histone modifications, DNA methylation also plays a critical role 42 ; this process is dynamic via addition by methyltransferases, and removal by 10 to 11 translocations (TET) methylcytosine dioxygenases. Separately, O‐GlcNAc is also known to regulate both transcriptional and epigenetic regulation, and contribute to cellular memory 31 , 43 , 44 ; for example, O‐GlcNAcylation of transcription factor Sp1 protects it from degradation 45 , 46 and increases its transcriptional activity, 47 and O‐GlcNAcylation of TETs, responsible for active epigenetic DNA hydroxymethylation, 48 , 49 can lead to increased DNA hypomethylation. 50 , 51 , 52 Collectively, while the H3K4me mark provides a critical foundation for metabolic memory, the specific role of O‐GlcNAc and its potential modifiers like TET enzymes remains poorly understood. This provides the foundation to investigate whether “O‐GlcNAc memory” may play a role in cardiac pathology and contribute to metabolic memory.

Thus, in our current study, we used the dnOGAh model to transiently increase cardiomyocyte protein O‐GlcNAc levels for 2 weeks followed by a washout period and subsequently induce left ventricle pressure overload via transverse aortic constriction (TAC). We hypothesized that the transient increase in O‐GlcNAc would exacerbate adverse cardiac remodeling under subsequent pressure‐overload, consistent with the concept of O‐GlcNAc memory. In functional, gravimetric, histologic and transcriptomic measures, we found overall exacerbated cardiac pathology in hearts subjected to transiently increased cardiomyocyte O‐GlcNAc and TAC versus TAC alone. Additionally, we identified potential transcriptomic markers and driving mechanisms of the exacerbated cardiac pathology. Taken together, our findings support a novel concept of cardiomyocyte O‐GlcNAc memory and suggest key mechanisms of exacerbated cardiac pathology at the transcriptomic level and provide an initial characterization and foundational phenotyping of our novel model.

METHODS

Data Availability

Further materials and reagents used in experiments are found in the Supplemental Material: Major Resources Table. The data to support findings of this study are accessible upon request from the corresponding author. Files associated with the RNA‐sequencing for this study are found on NCBI GEO repository (GSE298401).

Animal Models and Experimental Design

All studies using mice were done in line with the Institutional Animal Care and Use Committee (IACUC) of the University of Alabama at Birmingham approved protocols (Animal project number: 20530). All procedures involving mice were also compliant with the National Institutes of Health Guide for the Care and Use of Laboratory Animals eighth edition and utilized the ARRIVE reporting system (Supplemental Material: Major Resources Table & ARRIVE Checklist).

We used the previously generated, validated, and characterized dnOGAh mouse. 27 , 38 , 53 In short, the dnOGAh mouse is a model for inducible, cardiomyocyte‐specific enhancement of protein O‐GlcNAcylation via the cross of previously described mouse α‐myosin heavy chain promoter driven codon optimized reverse tetracycline trans‐activator (α‐myosin heavy chain‐rtTA, ie, tet on (tON)) mice 54 with previously described tetracycline‐responsive element, enhanced green fluorescent protein, rat OGA splice variant (TRE‐enhanced green fluorescent protein‐dnOGA, ie, dnOGA) mice. 53 All study conditions, interventions, groups, and timepoints are outlined in the experimental schema (Figure 1); in more detail, both male and female, 8‐ to 10‐week‐old α‐myosin heavy chain‐rtTA (tON) single transgenic mice were used as controls (Con), and tON + dnOGA double transgenic mice were used as experimental (dnOGAh)—all mice were on the FVB/NJ strain. 2‐week long transgene induction was done via a single intraperitoneal injection of 100 μg doxycycline (MilliporeSigma, Burlington, MA, USA) in 0.9% NaCl solution and switched to 1 g/kg doxycycline‐supplemented NIH31 diet (Envigo, Madison, WI, USA) for 2 weeks. All mice (regardless of Con versus dnOGAh group) were doxycycline injected and fed doxycycline chow to control for any indirect effects of doxycycline treatment. 55 After 2 weeks of transgene induction, all mice had their cages changed and placed on standard chow for the remainder of the study; 2 weeks after returning to standard chow diet, transverse aortic constriction (TAC) or Sham/Control surgery (described in the next section) was performed on each mouse. Additionally, for all studies, eg, echocardiography, heart histology, gravimetric measures, molecular studies and left‐ventricle (LV) mRNA sequencing, and the mice were climate‐ and light‐control housed at 22 °C on a 12/12 hours light/dark cycle with ad libitum access to food and water throughout the entire study. At the end of the study after 9 weeks of TAC/Sham, mice were anesthetized via 2% isoflurane induction chamber inhalation, then euthanized via manual cervical dislocation followed by organ/tissue excision. Study was conducted in a cohort‐matching manner; specifically, cohort‐matched mice underwent the dnOGAh ON/OFF‐TAC experimental paradigm and were used by cohort for specific measurements/experiments ensuring cohort‐matched experimental and control mice for each result; subsequently, mortality/survival data for all mice used in the current study was compiled in the general survival curve analysis (Table S1). To standardize circadian effects, 56 , 57 , 58 , 59 all study terminations and tissue collection was performed between 6 am and 8 am., and all samples were flash frozen with liquid nitrogen and stored at −80 °C until subsequent follow up studies.

Figure 1. Experimental schema for transient cardiac O‐GlcNAc induction with subsequent pressure‐overload (also known as the dnOGAh ON/OFF‐TAC paradigm).

Figure 1

Schematic showing the experimental timeline and procedures for the dnOGAh ON/OFF‐TAC paradigm used in this study—from induction of dnOGA transgene via doxycycline (4 weeks before TAC), switching the transgene “off” via removal of doxycycline (2 weeks before TAC), and TAC procedure, to subsequent echocardiography and tissue harvesting for downstream analyses. Details of the study size are shown in Table S1.

Transverse Aortic Construction Surgery

To induce left ventricle pressure overload, we conducted transverse aortic construction (TAC) as previously described 60 , 61 , 62 ; specifically in our study, as shown in the experimental schema (Figure 1), 12‐ to 14‐week old mice (after they underwent 2 weeks on doxycycline chow and subsequent 2 weeks on standard chow) underwent either TAC or control (Sham) surgery. Mice were anesthetized via 2% isoflurane induction chamber inhalation then placed in a supine position on a heating pad set at 37 °C to maintain body temperature; anesthesia was maintained via 1.5% isoflurane and monitored via toe pinching. Fur from neck and chest were removed via topical depilatory cream, and the area was cleaned with ethanol and betadine. At the suprasternal notch, a ~0.5 to 1 cm transverse skin incision was made; then followed by a ~2 to 3 mm partial superior median sternotomy and the thyroid glands were retracted, to visualize the transverse aortic arch. TAC was induced by placement of a titanium clip (Teleflex Medical, Morrisville, NC, USA)—calibrated to a 30‐gauge needle external diameter—on the aorta between the brachiocephalic and left common carotid arteries. After clip placement, chest/sternum and overlying skin were sutured close. Immediately after surgery, mice received intraperitoneal injection of buprenorphine (1 mg/kg) for post‐operative pain relief. Sham procedure followed the same steps, but no clip was placed on the aortic arch. Echocardiography, as described below, of the transverse aortic arch at the clip location, and measurement of peak pressure gradient (mm Hg) across the constriction location, confirmed TAC induced left ventricle pressure overload following the surgery (Table S2).

Transthoracic Echocardiography

At the prespecified timepoints shown in the experimental schema (Figure 1) after 8 weeks of TAC/Sham, transthoracic echocardiography was performed on all mice in the study, as previously described. 25 , 38 In brief, the mice were anesthetized via 2% isoflurane induction chamber inhalation then placed in a supine position on a heated echocardiography platform (Vevo integrated rail system, VisualSonics) set at 37 °C to maintain body temperature; sedation was maintained via nose cone inhalation of 1.0% to 1.5% isoflurane which allowed for heart rate maintenance of ~400 beats/minute. Fur from the chest was removed via topical depilatory cream, and then the mice were then placed in a left‐lateral‐decubitus position. Image acquisition was obtained on a Vevo 770 high‐resolution in vivo micro‐imaging system (VisualSonics) using an RMV‐707B 30 MHz ultrasound probe (VisualSonics); subsequently, images were analyzed on the Vevo 770 software using the Cardiac Measurements Package (VisualSonics). This software and package allowed for measurement and calculation in M‐mode images of various cardiac parameters such as ejection fraction, stroke volume, fractional shortening, and cardiac output; additionally, measurements such as LV internal dimension and posterior wall thickness, and interventricular septal thickness at both diastole (;d) and systole (;s).

Western Blotting

Detection and analysis of specific proteins and pan‐protein O‐GlcNAcylation was done via western blotting as previously described and optimized. 27 , 38 , 63 In brief, total LV tissue was homogenized and protein extracted using radioimmunoprecipitation assay buffer consisting of 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM Tris‐pH 7.5, 1% NP‐40, 1% sodium deoxycholate, 1 mM Na3VO4, 10 μM Thiamet‐G (SML0244, MilliporeSigma), Halt protease/phosphatase inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA, USA), and 10 μM phenylmethylsulfonyl fluoride (PMSF) (36978, ThermoScientific). 20 to 30 μg of protein lysate was loaded in each lane and separated on 8 or 12% sodium dodecyl sulfate polyacrylamide gels, then transferred to a 0.45 μm immobilon‐FL polyvinylidene fluoride (PVDF) membrane (IPFL00010, MilliporeSigma); note that the transfer of protein O‐GlcNAcylation blots used transfer buffer containing 0.375% sodium dodecyl sulfate, as described previously. 63 Membranes were immunoblotted using primary antibodies for specific proteins—OGA (14711‐1‐AP, ProteinTech), OGT (O6264, MilliporeSigma), and β‐actin (GTX629630, GeneTex), β‐Tubulin (ab131205, Abcam)—in 1× casein blocking buffer (B6429, MilliporeSigma). Fluorescence conjugated secondary antibodies—either goat anti‐rabbit IgG (A21109, ThermoScientific) or donkey anti‐mouse IgG (936‐32212, Li‐Cor Biosciences, Lincoln, NE, USA)—were used for protein detection, and membranes were scanned on the Odyssey CLx infrared imaging system (9120, Li‐Cor Biosciences). For protein O‐GlcNAcylation, membranes were immunoblotted using a primary antibody—CTD110.6 (UAB Epitope Recognition and Immunoreagent Core)—in 3% Bovine Serum Albumin (BSA) blocking buffer (sc‐2323, Santa Cruz Biotechnology). Protein detection used secondary goat anti‐mouse IgM‐HRP (401225, Calbiochem) and SuperSignal West Pico PLUS Chemiluminescent Substrate (34580, ThermoScientific) and was captured on an Amersham Imager 600 (GE Health Care, Chicago, IL, USA). All western blot images were analyzed on Image Studio Lite (Li‐Cor Biosciences).

Histological Staining and Analysis

Histological studies were performed as previously described. 38 In brief, medial, transverse LV tissue sections were fixed in 10% formaldehyde (F8775, Millipore‐Sigma) and embedded in paraffin. Subsequent histology sectioning, slide mounting, and staining (for both hematoxylin & eosin and Trichome stains) were performed at the UAB Comparative Pathology Laboratory. Staining was confirmed and images captured via light microscopy (Nikon Eclipse E200 with NIS element software); both quantification of trichrome signal, hematoxylin & eosin signal, and measurement of cross‐sectional cardiomyocyte cell area was performed in ImageJ Software (National Institutes of Health).

RNA‐Isolation for Sequencing and mRNA Sequencing Analysis

Bulk RNA sequencing was performed on whole LV tissue from both male and female mice in each of the 4 experimental conditions, as shown in the experimental schema (Figure 1; n=5 per sex, per group). RNA was isolated from LV tissue using the RNeasy® Fibrous Tissue Mini Kit (Qiagen Inc.), following the manufacture's protocol. To ensure quality, isolated RNA was analyzed to have an RNA integrity number of at least 7. Subsequent library preparation, quality control, and sequencing steps were formed by the UAB Heflin Center for Genomic Studies, Genomics Core Laboratory; next‐generation RNA sequencing was performed on a NovaSeq 6000 system (Illumina), generating paired‐end 100‐bp reads. Full details on the upstream processing and downstream analyses of the RNA sequencing data for this study can be found in the associated GitHub repository https://github.com/samuelfchang/dnOGA_ONOFF_TAC_RNA_Seq_Proj. In brief, upstream processing was performed on the UAB IT Research Computing, High Performance Computing fabric (a.k.a., “Cheaha”), referencing the nf‐core pipeline for RNA sequencing upstream processing (nf‐core/rnaseq v3.18.0) 64 ; specifically, aligned to mouse genome GRCm39 (GENCODE release M32). Downstream analyses and visualization were performed using R (v4.3.1), in R‐Studio (v2024.12.0+467), with differential gene expression analysis performed using and following documentation for DESeq2 (v1.40.2), 65 and as previously described. 38 Specifically, using DESeq2, differential gene expression quantification and significance testing was determined with the Wald test which output: quantile‐normalized read counts (via negative binomial generalized linear model fitting), log2 fold change for each contrast (changes in gene expression in pairwise comparisons between each of the experimental groups), P values, and Benjamini‐Hochberg adjusted P values (false discovery rate [FDR], or FDR/q‐values). Further analyses and data visualization came from importing these results into: VennPlex 66 to compare and visualize differentially expressed genes (DEG) of the various contrasts (DEG filtering cutoff: q<0.05 & fold change ≥|1.5|), STRING database (STRING‐db) 67 for gene level associated protein–protein interaction networks and pathway analysis (STRING‐db parameters: Network type‐ Full STRING network, Required score‐ medium confidence at 0.400, FDR stringency <0.05) for DEGs (filtering cutoff: q<0.05 & fold change≥|1.5|), and Pathview 68 using KEGG 69 , 70 , 71 data for biological pathway analysis and visualization for DEGs (q<0.05).

Files for the RNA‐sequencing in this study are found on the NCBI GEO repository (GSE298401); and all details on the upstream processing and downstream analyses (eg, packages, parameters, and code) for the RNA sequencing data in this study can be found in the associated GitHub repository: https://github.com/samuelfchang/dnOGA_ONOFF_TAC_RNA_Seq_Proj.

Statistical Analysis

For experiments analyzed using parametric methods, assumptions of normality of variance were assessed before analysis based on results of pilot studies. 72 Statistical analyses were performed using GraphPad Prism 10.4.1 on MacOS × (GraphPad Software). Analyses included 2‐way ANOVA followed by Tukey's multiple comparisons test. For experiments with small sample sizes (n<10), including western blot analysis, cell area measurements, and perivascular fibrosis analysis, statistical significance was assessed using permutation tests. The permutation tests were performed in R (permuco or coin packages) using 10 000 random permutations of group labels to generate a null distribution of the test statistic. Two‐sided P values were calculated as the proportion of permuted test statistics that were equal to or more extreme than the observed statistic. Results are presented as Mean±SEM, with cutoff for statistical significance set at P<0.05. For survival analysis, survival curves were analyzed via Log‐Rank (Mantel‐Cox) Test. Results are presented as χ2 and degrees of freedom, with cutoff for statistical significance set at P<0.05. Survival proportions were compared using Fisher's Exact Test, with cutoff for statistical significance set at P<0.05. For quantification of exacerbated pathology/change in measurements, Bliss independence analysis was used to assess synergy. 73 Results are presented as combination index (CI) with cutoff for synergy set at CI<1. For RNA sequencing data, as mentioned earlier, using DESeq2, differential gene expression quantification and significance testing was determined with the Wald test. Specific gene normalized read count (normalized counts) results were graphed in GraphPad Prism and presented as Mean±SEM; and statistical significance was pulled from the DESeq2 Wald Test results for P<0.05, q<0.1, and q<0.05.

Graphics Generation

Experimental Schema (Figure 1) and elements of the graphical abstract were generated using BioRender Software (BioRender, Toronto, Ontario, Canada). 74 , 75

RESULTS

Transient Cardiomyocyte‐Specific O‐GlcNAc Induction (dnOGA ON/OFF) With Subsequent Pressure Overload and Levels of Cardiac Total Protein O‐GlcNAc

We previously reported the dnOGA transgene is specifically expressed in hearts of tON‐dnOGA, double transgenic, mice when doxycycline is present, 27 and that cardiomyocyte dnOGA expression leads to a significant increase in cardiac protein O‐GlcNAcylation at 2 weeks of dnOGA induction. 27 , 38 We confirm these finding here demonstrating doxycycline induces the dnOGA transgene with a corresponding significant increase in protein O‐GlcNAcylation at 2 weeks of induction (Figure S1C through S1F). However, we observe no significant difference in cardiac protein O‐GlcNAcylation and cardiac hypertrophy across the 4 experimental groups at the end of the dnOGAh ON/OFF‐TAC paradigm (Figure 2A and 2B; Figures S1A, S1E, S1F, and S2A through S2C). OGA levels (Figure 2C; Figure S2E) do not change after 2 weeks back on standard chow or between any of the experimental end groups. OGT levels only modestly increase in the Con‐TAC versus Con‐Sham comparison (Figure 2D). Additionally, we observed no differences in survival curves between female and male mice, as well as between the 4 experimental groups (Table S1). Taken together, these results show that in this model of transiently enhanced cardiomyocyte protein O‐GlcNAc and subsequent pressure‐overload achieves a temporary increase in cardiac protein O‐GlcNAcylation with a subsequent return to control levels of cardiac protein O‐GlcNAcylation before TAC or Sham surgery.

Figure 2. Transient cardiomyocyte‐specific O‐GlcNAc induction (dnOGA ON/OFF) with/without pressure overload shows no change in cardiac total protein O‐GlcNAc levels compared with respective controls: a validation of the dnOGAh ON/OFF model.

Figure 2

A, Western blot assay of left ventricle (LV) whole cell protein extract for protein O‐GlcNAcylation (via CTD110.6), protein levels of endogenous/WT OGA (lower band), dnOGA (upper band because of eGFP fusion), and OGT for Con‐Sham, Con‐TAC, ON/OFF‐Sham and ON/OFF‐TAC conditions. B–D, Densitometry analysis of all immunoblots. B, Top panel: quantification of whole‐lane cardiac protein O‐GlcNAcylation (20–250 kDa protein size). Bottom panel: quantification of cardiac protein O‐GlcNAcylation at 50 to 250 kDa protein size. C, Quantification of endogenous/WT OGA protein. D, Quantification of OGT. All quantitative data are mean±SEM (n≥9); Statistical significance was based on 2‐sided permutation test.

Transient Cardiac O‐GlcNAc Induction With Subsequent Pressure‐Overload Induces Cardiac Hypertrophy, Fibrosis, and Dysfunction

First, we performed a baseline assessment following 2 weeks of dnOGA ON/OFF before TAC surgery and confirmed that there were no significant changes in heart size in either males or females (Figure S3A). Consistent with the known effects of pressure overload, total‐heart weight, LV‐weight, and LV cross‐sectional cardiomyocyte cell area increased significantly in the Con‐TAC and ON/OFF‐TAC versus respective Sham conditions (Figure 3A through 3C and 3E), with no change of RV weight in any group (Figure S3B). Importantly, total‐heart weight, LV‐weight and LV cardiomyocyte cell area all show further significant increase in ON/OFF‐TAC versus Con‐TAC groups—with no significant differences in any index of hypertrophy between ON/OFF‐Sham versus Con‐Sham groups with individual sex differences presented in Figure S3C through S3F.

Figure 3. Transient cardiac O‐GlcNAc induction with subsequent pressure‐overload induces further cardiac hypertrophy, perivascular fibrosis and dysfunction compared with pressure‐overload alone.

Figure 3

A, Normalized ratio of total heart weight to tibia length (TL), and B, left ventricle (LV) plus septum to TL, for Con‐TAC and ON/OFF‐TAC mice compared with age‐matched Sham controls (Con‐Sham and ON/OFF‐Sham) (n≥27). C, D, Representative images from histological examination of LV cardiac tissue using hematoxylin and eosin (H&E) staining (C), and perivascular LV cardiac tissue H&E and trichrome staining (D). E, Average cross‐sectional LV cardiomyocyte cell area for Con‐TAC and ON/OFF‐TAC mice compared with age‐matched Sham controls (Con‐Sham and ON/OFF‐Sham) (n≥7). F, Normalized ratio of trichrome to H&E signal of perivascular LV tissue for Con‐TAC and ON/OFF‐TAC mice compared with age‐matched Sham controls (Con‐Sham and ON/OFF‐Sham) (n≥8). G, Normalized ratio of wet‐dry lung weight to TL for Con‐TAC and ON/OFF‐TAC mice compared with age‐matched Sham controls (Con‐Sham and ON/OFF‐Sham) (n≥29). Results for previous measures split by sex are found in Figure S3. Statistical significance was based on: 2‐way ANOVA followed by Tukey multiple comparisons test (A, B), 2‐sided permutation test (E–G) and 1 way permutation test (F #). All calculated and analysis data are mean±SEM.

Given the known association between pathologic cardiac hypertrophy and fibrosis, 76 , 77 we evaluated LV tissue fibrosis across the 4 experimental groups. Using histologic measurement of trichrome staining in LV tissue, perivascular fibrosis significantly increased in both Con‐TAC and ON/OFF‐TAC groups compared with their respective Sham controls (Figure 3D and 3F and individual sex differences presented in Figure S3G). Moreover, perivascular cardiac fibrosis further increases in ON/OFF‐TAC versus Con‐TAC groups. Meanwhile, interstitial fibrosis showed no significant change between the 4 groups (Figure S4F and S4G).

With results showing further increases in both LV hypertrophy and peri‐vascular fibrosis, we assessed cardiac function across the 4 experimental groups. Pulmonary edema, as an indicator of hemodynamic compromise, 78 showed no significant change in the Con‐TAC versus Con‐Sham comparison, but importantly, significantly increased in the ON/OFF‐TAC versus ON/OFF‐Sham and ON/OFF‐TAC versus Con‐TAC comparisons (Figure 3G); this showed pulmonary edema further increased significantly in ON/OFF‐TAC versus ON/OFF‐Sham groups compared with Con‐TAC versus Con‐Sham groups. Measures of cardiac function via echocardiography show expected decreases in ejection fraction in both Con‐TAC and ON/OFF‐TAC groups compared with their respective Sham controls (Figure S5A), but no further decrease in the ON/OFF‐TAC versus Con‐TAC groups.

Taken all together, across the various cardiac hypertrophy, fibrosis, and function measures, transiently increased cardiac protein O‐GlcNAcylation with subsequent pressure‐overload further significantly increased cardiac pathologic remodeling compared with pressure‐overload alone. Specifically, results show further increases in LV cardiomyocyte hypertrophy, perivascular fibrosis, and pulmonary edema—not attributable to further impaired systolic function.

Transcriptomic Analyses of Transiently Increased Cardiac Protein O‐GlcNAc With Subsequent Pressure‐Overload Both Confirm Markers and Identify Novel‐Pathways of Exacerbated Pathologic Cardiac Remodeling

In light of our earlier work demonstrating the effect of sustained increased cardiomyocyte protein O‐GlcNAcylation on the LV transcriptome, as well as the known role of O‐GlcNAc to regulate transcriptional and epigenetic regulation, 31 , 38 we performed mRNA sequencing to identify and examine the impact of transiently increased cardiomyocyte protein O‐GlcNAc with subsequent TAC on the global LV transcriptome. After relevant quality control, filtering, and normalization (Figure S6A through S6I), unsupervised principal component analysis (PCA) showed distinct transcriptomic profiles, separated by principal component 1, of each of the 4 experimental groups (Figure S6H); filtering for differentially expressed genes (DEGs) shown via Volcano plot (Figure S7A), and frequency tables of various significance cutoffs (Figure S7B). Full tables of DEGs at various significance cutoffs are found in Table S3, with key in Table S4. Candidate search for genes related to our phenotypic results in previous figures show that transcriptomic markers for cardiac hypertrophy, fibrosis and dysfunction all follow the pattern of significant further changes in the ON/OFF‐TAC versus Con‐TAC comparison; for instance, related to cardiac structure and hypertrophic remodeling, My6 (α‐myosin heavy chain) expression significantly decreases in the ON/OFF‐TAC versus Con‐TAC comparison (Figure S8A). With regards to fibrosis, Col1a1 (Collagen type 1 α‐1) expression across the 4 groups recapitulates the changes we show in peri‐vascular fibrosis (Figure 3D and 3F) and shows further significant increase in expression shown in the ON/OFF‐TAC versus Con‐TAC groups (Figure S8B). Also, Nppa (Atrial natriuretic peptide, ANP) expression, as a marker of cardiac dysfunction, shows further significant increase in expression shown in the ON/OFF‐TAC versus Con‐TAC comparison (Figure S8C). Additional gene markers of pathologic cardiac remodeling follow similar patterns of significant change (Figure S8D through S8I). Taken as a whole, the expression changes in these specific gene markers transcriptomically support our previous phenotypic results of furthered pathologic cardiac remodeling.

Beyond transcriptomic confirmation of furthered pathology, subsequent analysis of DEGs (filtered at FDR/q‐value <0.05 and |fold change|≥1.5) via Venn analysis uncovers potential drivers and effectors of the furthered pathology we observe in our phenotypic results. Venn analysis resolves DEGs associated with various overlapping comparisons between the 4 experimental groups (Figure 4A), and we specifically focus on DEGs associated with the key comparison of further changed expression in the ON/OFF‐TAC versus Con‐TAC groups; a table of what each Venn region represents in terms of significant changes in the various comparisons are shown in Table S5, with all DEGs from the 4‐way Venn diagram found in Table S6. To identify transcriptomic pathways and regulatory mechanisms within the DEGs of the Venn analysis, we perform pathway enrichment following network interaction analyses using STRING‐db on the up‐ and down‐regulated DEGs from the key ON/OFF‐TAC versus Con‐TAC comparison.

Figure 4. Venn diagram of DEGs from relevant pairwise comparisons and pathway analyses of DEGs from key Venn regions reveal transcriptomic markers of pathology exacerbation.

Figure 4

A, Venn diagram of DEGs from 4 comparisons between experimental groups; table of all DEGs found in the various regions of the Venn diagram are found in Table S6. B, C, Pathway enrichment analysis of DEGs using STRING‐db with Gene‐Ontology (GO) and UniProt Keyword databases; top significantly enriched pathways for upregulated DEGs in regions (B), and top significantly enriched pathways for downregulated DEGs in regions (C). Table of all enriched pathways and regulated genes within each are found in Table S7. Differentially expressed genes were identified using criteria of FDR<0.05 and |fold change|>1.5.

In Figure 4B and 4C, we show significantly enriched pathways for 3 important Venn diagram regions associated with furthered significant changes in the ON/OFF‐TAC versus Con‐TAC comparison. The top upregulated pathways for all 3 regions were associated with extracellular matrix (ECM) and fibrosis pathways (Figure 4B): examples include, ECM (GO0031012), collagen‐containing ECM (GO0062023), basement membrane (GO0005604), collagen fibril organization (GO 0030199), cell adhesion (GO 0007155), and extracellular region (GOCC0005576). Top downregulated pathways across the 3 regions include (Figure 4C): Glycoprotein (UniProt KW‐03525, protein containing one or more covalently linked carbohydrates of various kinds), regulation of heart contraction (GO), regulation of blood circulation (GO), cation transmembrane transport (GO), immune system process (GO) and Immune response (GO). All significantly enriched pathways from the DEGs of the Venn diagram can be found in Table S7. From the pathway analysis of DEGs from key regions in the 4‐way Venn analysis, transcriptomic signatures identify biological/molecular pathways which could potentially drive the furthered cardiac pathology seen in O‐GlcNAc memory with subsequent pressure‐overload.

DEGs From Pathway Analysis and Candidate DEGs Identify Specific Transcriptomic Drivers of Pathology Exacerbation From Transiently Increased Cardiac Protein O‐GlcNAc With Pressure‐Overload

Examining the individual DEGs which make up the significantly enriched up‐ and down‐regulated pathways in Figure 4, we find key DEGs that encode proteins associated specifically within the context of furthered cardiac pathology. In the enriched upregulated pathways associated with ECM/fibrosis/collagen, we find upstream “driver” regulatory mechanisms for ECM associated pathologic cardiac fibrotic remodeling (Figure 5A and 5B; Figure S9A). Examples include: Ccn2 (Connective tissue growth factor, CTGF; Figure 5A), and Postn (Periostin; Figure 5B); in both DEGs, the Con‐TAC versus Con‐Sham and ON/OFF‐TAC versus ON/OFF‐Sham comparisons show significantly increased gene expression, and importantly, the key ON/OFF‐TAC versus Con‐TAC comparison shows significantly further increased expression.

Figure 5. DEGs from pathway analyses of key Venn regions and candidate DEGs identify potential transcriptomic drivers of pathology exacerbation.

Figure 5

A–I, Specific DEGs from mRNA sequencing of LV tissue (n=5 per sex, per group) in normalized counts that were significantly enriched in pathway analysis of Figure 4. A, B, Specific DEGs from pathways associated with extracellular matrix/fibrosis/collagen: Connective tissue growth factor (CTGF) (Ccn2), and Periostin (Postn). C–E, Specific DEGs from pathways associated with heart contraction/function and ion transport: potassium channels (Kcnd2), subunit of a voltage‐gated sodium channel (Scn10), and corticotropin‐releasing hormone receptor 2 (Crhr2). F, G, Specific DEGs from pathways associated with glycosylated proteins: β‐1A adrenergic receptor for catecholamine binding (Adra1b), and hyperpolarization‐activated cyclic nucleotide‐gated potassium channel 4 (Hcn4). D–I, Specific DEGs associated with calcium signaling: sarcoplasmic/endoplasmic reticulum Ca2+‐ATPase 2a (SERCA2a) (Atp2a2), and stromal interaction molecule 1 (Stim1). Statistical significance was based on Wald test (A–I). All calculated and analysis data are mean±SEM.

Investigating DEGs from the significantly enriched downregulated pathways associated with heart contraction/function and ion transport, the majority of key DEGs encode proteins associated with some form of cardiac ion transport (Figure 5C through 5E; Figure S9B): for example, Kcnd2 encodes a potassium channel (Figure 5C), and Scn10a encodes the subunit of a voltage‐gated sodium channel (Figure 5D). And other specific DEGs include genes which encode receptor proteins for hormones which can influence cardiac function/rhythm, such as Crhr2 (corticotropin‐releasing hormone receptor 2; Figure 5E). Similarly, although significantly enriched in a different pathway associated with glycosylated proteins, key DEGs from this downregulated pathway also primarily encode proteins associated with either ion transport or hormones impacting cardiac function/rhythm (Figure 5F and 5G; Figure S9C): Adra1b (β‐1A adrenergic receptor for catecholamine binding; Figure 5F), and Hcn4 (hyperpolarization‐activated cyclic nucleotide‐gated potassium channel 4; Figure 5G).

Observing the trend of key ion transport DEGs from the downregulated pathway analyses, we perform a candidate search for DEGs associated with calcium handling/signaling based on our previous publication (Figure 5H and 5I; Figure S9D). 38 Some examples include: Atp2a2 encoding Sarcoplasmic/endoplasmic reticulum Ca2+‐ATPase 2a (SERCA2a; Figure 5H). And Stim1 encoding known O‐GlcNAcylation target stromal interaction molecule 1 79 is only upregulated in the Con‐TAC versus Con‐Sham comparison (Figure 5I). Returning to the pathway analysis, investigating the DEGs from the significantly enriched downregulated pathways also shows some genes associated with immune system processes. Taken as a group, these DEGs appear to be generally associated with B‐cell immunity (Figure S9E); for example, Bcl11a (B‐cell lymphoma/leukemia 11a), and Shld1 (Shieldin complex subunit 1) which plays a role in immunoglobulin class‐switch recombination and DNA‐repair in B‐cells. 80 Taken all together, filtering and analysis of key individual DEGs from pathway analyses identifies cardiac relevant genes, encoding proteins associated with key biological processes in the heart, which could indicate transcriptionally upstream drivers of the furthered cardiac pathology we show in previous figures.

Transiently Increased Cardiac Protein O‐GlcNAc With Subsequent Pressure‐Overload Causes Transcriptomic Changes Associated With Altered Redox Mechanisms, Cardiac Metabolism, and Mitochondria

Previous studies demonstrate a clear link between increased cardiac protein O‐GlcNAc and decreased mitochondrial function 25 , 27 , 81 ; specifically, our previous publication on sustained cardiomyocyte protein O‐GlcNAcylation showed not only transcriptomic and proteomic changes in redox mechanisms and suppressed energy metabolism/mitochondrial pathways in the heart, but also, reduced oxidative phosphorylation (OXPHOS) mitochondrial function. 38 In our current study, with regards to changes in redox mechanisms, Nox4 (NADPH‐Oxidase 4, NOX4) expression significantly increases in the ON/OFF‐TAC versus ON/OFF‐Sham comparison while non‐significantly changed in Con‐TAC versus Con‐Sham comparison; importantly, Nox4 expression significantly increases in the key ON/OFF‐TAC versus Con‐TAC comparison (Figure 6A). NOX4 is a cardiac reactive oxygen species producer that is heavily implicated in the cardiac response to metabolic syndrome and/or pressure overload stressors. 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 Another isoform of NOX, Cybb encoding NOX2, only significantly increases in the ON/OFF & TAC comparison (Figure S10A). Conversely, mitochondrial antioxidant process gene Sod2, Superoxide dismutase 2 mitochondrial, expression significantly decreases in the ON/OFF‐TAC versus ON/OFF‐sham comparison and key ON/OFF‐TAC versus Con‐TAC comparison (Figure 6B); furthermore, expression of key regulator of redox pathways and known O‐GlcNAcylation target, 90 Nfe2l2 encoding nuclear factor erythroid 2‐related factor 2, increases only in the Con‐TAC versus Con‐Sham comparison—at raw P value <0.05 (Figure 6C).

Figure 6. Transient cardiac O‐GlcNAc induction with subsequent pressure‐overload changes transcriptomic profiles associated with redox mechanism, and cardiac metabolism.

Figure 6

A–K, Specific candidate DEGs from mRNA sequencing of LV tissue (n=5 per sex, per group) in normalized counts. A–C, Specific DEGs associated with redox mechanisms: NADPH‐Oxidase 4 (Nox4), superoxide dismutase 2 mitochondrial (Sod2), Nuclear factor erythroid 2‐related factor 2 (Nfe2l2). D–F, Specific DEGs associated with cardiac metabolism: glucose transporter GLUT4 (Slc2a4), Pyruvate dehydrogenase kinase 2 (Pdk2), Citrate synthase (Cs). Other DEGs associated with the citric acid cycle are found in Figure S11. G–K, Specific DEGs associated with the electron transport chain: NADH:ubiquinone oxidoreductase subunit B2 of Complex I (Ndufb2), succinate dehydrogenase complex subunit B of Complex II (Sdhb), Cytochrome c1 of Complex III (Cyc1), Cytochrome c oxidase subunit 5A of Complex IV (Cox5a), ATP synthase subunit O of Complex V (Atp5po). Other DEGs associated with the electron transport chain are found in Figure S12. Statistical significance was based on Wald test (A–K). All calculated and analysis data are mean±SEM.

In terms of genes associated with metabolic processes, we first explored key DEGs encoding proteins involved in glucose metabolism. Slc2a4 expression, encoding the predominant cardiac glucose transporter GLUT4, significantly decreased in both Con‐TAC versus Con‐Sham and ON/OFF‐TAC versus ON/OFF‐Sham comparisons, and importantly significantly further decreased in the ON/OFF‐TAC versus Con‐TAC comparison (Figure 6D). Linking glycolysis and mitochondrial glucose oxidation, Pdk2 (Pyruvate dehydrogenase kinase 2) expression significantly decreases in both the ON/OFF‐TAC versus ON/OFF‐Sham and ON/OFF‐TAC versus Con‐TAC comparisons (Figure 6E); however, both the Pdk1 and Pdk4 isoforms are not significantly changed in any comparison (Figure S10B). Furthermore, investigating the genes encoding enzymes of the tricarboxylic acid cycle, Cs (citrate synthase) expression is significantly decreased in all 4 comparisons—although ON/OFF‐Sham versus Con‐Sham comparison is only via raw P value (Figure 6F); and generally, other tricarboxylic acid cycle genes exhibit similar significantly decreased expression across a combination of the 4 comparisons (Figure S11).

Moving to mitochondrial OXPHOS complex associated genes, select DEGs representative of each of the OXPHOS complexes show similar significant downregulation in both ON/OFF‐TAC versus ON/OFF‐Sham and the ON/OFF‐TAC versus Con‐TAC comparisons: Ndufb2 (encoding NADH:ubiquinone oxidoreductase subunit B2 of Complex I; Figure 6G), Sdhb (encoding succinate dehydrogenase complex subunit B of Complex II; Figure 6H), Cyc1 (encoding Cytochrome c1 of Complex III; Figure 6I), Cox5a (encoding Cytochrome c oxidase subunit 5A of Complex IV; Figure 6J), and Atp5po (encoding ATP synthase subunit O of Complex V; Figure 6K). To provide a wider view, DEGs—for the ON/OFF‐TAC versus Con‐TAC comparison (at q<0.05) imported into KEGG Pathview—return a global OXPHOS visualization of associated gene regulation (Figure S12); like our candidate approach (Figure 6G through 6K), the KEGG pathway visualization shows global decreased gene expression across OXPHOS complex associated genes in the ON/OFF‐TAC versus Con‐TAC comparison.

With all the changes in metabolism associated gene expression, we investigated regulatory processes of mitochondrial homeostasis and oxidative capacity. First, Ppargc1a expression (encoding PPARG coactivator 1 alpha, PGC‐1α), a key transcriptional coactivator and regulator of mitochondrial biogenesis, 91 significantly decreased in both the ON/OFF & TAC and ON/OFF‐TAC versus Con‐TAC comparisons (Figure S10C); interestingly, the β isoform (Ppargc1b/PGC‐1β) expression decreased in the ON/OFF‐sham versus Con‐Sham and ON/OFF‐TAC versus Con‐TAC comparisons (Figure S10C).

Finally, as the hexosamine biosynthetic pathway, which synthesizes the post‐translational modification residue for O‐GlcNAcylation—UDP‐GlcNAc, also branches off from glycolysis, we investigated whether O‐GlcNAc memory with subsequent pressure‐overload affects hexosamine biosynthetic pathway genes; Gfpt1 expression, encoding the hexosamine biosynthetic pathway rate‐limiting enzyme glutamine‐fructose‐6‐phosphate transaminase 1, does not significantly change in any of the comparisons (Figure S10D), and Uap1 (UDP‐N‐acetylglucosamine pyrophosphorylase) expression levels only significantly decrease in the ON/OFF‐TAC versus Con‐TAC comparison (Figure S10D).

Taking all the candidate DEG analysis together, our results show that O‐GlcNAc memory with subsequent pressure‐overload further changes gene expression in the key ON/OFF‐TAC versus Con‐TAC comparison associated with redox mechanisms, metabolism and mitochondrial homeostasis.

DISCUSSION

The current study tested the hypothesis that a transient increase in cardiomyocyte protein O‐GlcNAcylation leads to exacerbated adverse cardiac remodeling following subsequent pressure overload. The overall rationale for this study is based in the results of the DCCT/EDIC studies, which found a significant increase in major adverse cardiovascular event rates for patients with diabetes on conventional glycemic management during DCCT then switched to tight glycemic control therapy during EDIC versus patients always on tight glycemic control therapy (ie, goal HbA1c at near‐normal ranges) 9 , 10 , 11 , 12 ; these results, along with studies such as the UKPDS and VADT for type‐2 diabetes, introduce the concept of metabolic memory and how it affects long‐term outcomes for diabetic patients. 14 , 15 , 16 , 17 Potential genetic/molecular mechanisms underlying metabolic memory include epigenetic modifications—for example, changes in DNA or histone methylation status attributable to previous hyperglycemia. 18 , 19 , 39 , 40 , 41 Recent research on cardiac O‐GlcNAcylation in the context of CVD and diabetes lays the scientific foundation for investigation O‐GlcNAc as a key factor in the development of diabetic cardiac pathology. For example, Prakoso et al showed not only increased cardiac O‐GlcNAc in diabetic patients versus non‐diabetic patients, but also a significant positive correlation between increasing cardiac O‐GlcNAc and LV dysfunction. 28 Furthermore, our recent work studying effects of sustained cardiomyocyte O‐GlcNAc enhancement recapitulates many hallmarks of pathology seen in diabetic hearts. 38 Related to potential mechanisms of metabolic memory, O‐GlcNAc is also known to play a role in both transcriptional and epigenetic regulation, and can affect cellular memory 31 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 ; consequently, O‐GlcNAc is a potential mediator of metabolic memory.

Protein O‐GlcNAcylation is a highly dynamic and tightly regulated mechanism. 31 We used the dnOGAh model to modulate protein O‐GlcNAc. The primary rationale for selecting this model is that it is a known OGA splice variant originally identified in spontaneously diabetic rats. 92 , 93 Notably, this variant was confirmed to inhibit O‐GlcNAcase activity while preserving histone acetyltransferase activity. 94 By using dnOGAh, we aimed to mitigate potential confounding variables that arise from the complete overexpression or knockout of OGT and OGA. This approach allowed us to induce a moderate and physiologically relevant change in protein O‐GlcNAc, specifically in the context of processes such as chromatin structure change 51 and noncatalytic activity such as host cell factor 1 cleavage activity by OGT. 95 A key advantage of this system is its capability to precisely control the tissue‐specific expression, timing, and duration of the overexpression using doxycycline. This doxycycline‐inducible feature makes the model particularly well‐suited for a “memory” study, where gene expression is regulated by the administration and subsequent withdrawal of doxycycline. While previous studies confirmed changes in OGA and OGT protein expression level upon dnOGAh overexpression, 38 this alteration was not sustained after the cessation of induction (doxycycline OFF). The net result of their activities can be indirectly verified through Protein O‐GlcNAc Western blot analysis; however, direct assessment of OGT and OGA activities within the cells currently remains to be determined.

We demonstrated that the dnOGAh ON/OFF model as a novel approach for examining the potential role of cardiomyocyte O‐GlcNAc in mediating metabolic memory (Figure 2A and 2B; Figures S1A, S1B, and S2A through S2D). Initially, we evaluated whether transient dnOGA induction resulted in baseline cardiac hypertrophy before TAC surgery (Figure S3A). We confirmed that no hypertrophic phenotype was observed in either male or female mice at baseline. This finding is consistent with our previous study, which showed that a 2‐week induction of dnOGA does not elicit immediate structural remodeling. 38 This absence of overt changes in the absence of secondary stress was further supported by our transcriptomic analysis; the comparison between the ON/OFF‐Sham and Con‐Sham groups revealed only 28 DEGs, in contrast to the 569 DEGs identified between the ON/OFF‐TAC and Con‐TAC groups (Figure S7B). While more detailed longitudinal functional and transcriptomic profiling may be warranted, our current results indicate that transient O‐GlcNAc elevation alone does not significantly alter cardiac structure or the global transcriptome without a secondary stressor. Consistent with many other studies, we demonstrated that TAC resulted in increased cardiac hypertrophy, fibrosis and decreased systolic function (Figure 3). 37 , 61 , 62 , 96 , 97 , 98 , 99 We found no significant increase in cardiac O‐GlcNAc levels in response to TAC, which is in contrast to several other studies. 37 , 96 , 98 , 99 However, other reports show no significant increase in O‐GlcNAc following TAC, 97 , 98 consistent with our own results (Figure 2A and 2B). This variability in changes in O‐GlcNAc levels in response to TAC is likely attributable to the variety of different pressure overload paradigms using TAC. For example, Zhu et al showed that cardiac O‐GlcNAc increases at 1‐week post‐TAC but returned to control levels at 6‐weeks post‐TAC, 98 pointing towards a relationship cardiac O‐GlcNAc and the duration of TAC.

All measures of cardiac hypertrophy were exacerbated in the ON/OFF‐TAC versus Con‐TAC groups (Figure 3A through 3C and 3E), as defined by the magnitude of change between ON/OFF‐TAC versus ON/OFF‐Sham groups is greater than that of the combination of main‐effect changes either by Con‐TAC versus Con‐Sham and/or ON/OFF‐Sham versus Con‐Sham comparisons. We can also use basic synergy calculations to quantify exacerbation. 73 Applying these criteria to our results, we see that in total heart weight, LV weight, LV cardiomyocyte cell area and transcriptomic marker, the significant further increase between ON/OFF‐TAC versus ON/OFF‐Sham groups is greater than the main‐effect changes between the Con‐TAC versus Con‐Sham and ON/OFF‐Sham versus Con‐Sham groups. Exacerbation/synergy calculations for each show strong synergy for each measurement (CI=0.66 for total heart weight, CI=0.71 for LV weight, and CI=0.63 for LV cell area). Transcriptomically, markers of cardiac hypertrophy also show exacerbated decrease in expression using our definition of exacerbation (Figure S8A and S8D through S8F) and Nppa expression, as a classical marker of heart failure (HF), showed exacerbated increase in the ON/OFF‐TAC versus Con‐TAC (Figure S8C; CI=0.36). Cardiac fibrosis exacerbation is shown in perivascular fibrosis via histology (CI=0.59; Figure 3D and 3F) and strengthened by exacerbated increase fibrosis marker gene expression (Figure S8B and S8G through S8I). With measures of cardiac dysfunction, we also observed exacerbated hemodynamic compromise, as indicated by increased pulmonary edema and greater fluid accumulation in the lungs (Figure 3G).

In summary, the phenotypic measurements of cardiac pathology in the current study support the concept that O‐GlcNAc memory under subsequent TAC leads to exacerbated adverse LV cardiac hypertrophy, LV perivascular fibrosis, and pulmonary fluid retention; these results demonstrate the pathologic effects of O‐GlcNAc memory at the cardiovascular pathology/systems level.

As discussed in the introduction, O‐GlcNAc plays many roles in both transcriptional and epigenetic regulation 31 , 39 , 40 , 41 , 45 , 46 , 48 , 49 ; therefore, we performed mRNA sequencing of samples from the 4 groups of our study on O‐GlcNAc memory with subsequent pressure‐overload. We leveraged the scale of RNA sequencing data to start identifying the transcriptomic basis for potential driving molecular pathways of the exacerbated cardiac pathology seen in O‐GlcNAc memory. For the transcriptomic analysis, DEGs were identified using a stringent filtering criterion of FDR (q) <0.05 and a fold‐change threshold of ±1.5. Additionally, for network and pathway analysis, a q‐value <0.05 was established as the threshold for statistical significance. These rigorous criteria were employed to enhance biological relevance and minimize results driven by statistical analysis. Venn diagram analysis of the DEGs filters and identifies DEGs changing in various overlapping combinations of the 4 key comparisons within O‐GlcNAc memory with subsequent pressure‐overload (Figure 4A). DEGs of interest from specific Venn diagram regions were then imported into STRING‐db to perform network and pathway analyses; the significantly enriched biologic pathways from this analysis, at a global level, are all related to the current study's measures of exacerbated cardiac pathology such as cardiac hypertrophy, fibrosis and dysfunction (Figure 4B and 4C). Moreover, these pathways are potentially underlying biological/molecular drivers of exacerbated cardiac pathology seen in O‐GlcNAc memory with subsequent pressure‐overload.

Investigating the DEGs of the enriched pathways, we identify specific DEGs which help place the general biological pathways in the specific context of cardiac pathology (Figure 5). The DEGs associated with ECM/fibrosis are genes encode proteins which can drive fibrotic remodeling (Figure 5A and 5B; Figure S9A)—indicating potential molecular pathways behind the exacerbated fibrosis with known relevance to the heart. 100 , 101 , 102 , 103 , 104 For example, Ccn2 (connective tissue growth factor, CTGF; Figure 5A) is a known central mediator of pathologic fibrotic remodeling and can interact with transforming growth factor‐β (with Tgfb2 showing exacerbated increase expression in our data; Figure S9A) to induce and maintain fibrotic remodeling 105 , 106 ; and diabetic patients have 3× greater urine/plasma CTGF ratio compared with healthy subjects, 107 supporting clinical relevance of CTGF in diabetic patients. Additionally, CTGF is known to stimulate adhesion, migration and growth of various cell types associated with cardiac remodeling, such as myofibroblasts, fibroblasts and smooth muscle cells. 108 , 109 , 110 In the significantly enriched pathways for down‐regulated genes, the majority of DEGs are associated with heart contraction/function and ion transport and show exacerbated downregulation (Figure 5C through 5G; Figure S9B and S9C). Specifically, many DEGs encode proteins for various cation channels and hormonal regulation of cardiac rhythm. In candidate DEGs associated with calcium signaling, many show exacerbated downregulation (Figure 5H and 5I; Figure S9D). Importantly, the proteins encoded by these DEGs are known to be regulated (directly or indirectly) by O‐GlcNAc and associated with the diabetic state—again demonstrating potential molecular pathways by which O‐GlcNAc memory affects the cardiac environment. 43 , 111 , 112 , 113 , 114 , 115 , 116

Furthermore, we also compared DEGs from our current study to the results of our previous work on sustained cardiomyocyte O‐GlcNAcylation which identified and validated changes in redox mechanisms, OXPHOS function and mitochondrial homeostasis. 38 In our current study, we see changes associated with an imbalance in the antioxidant versus reactive oxygen species production. While Nox4 expression is not significantly regulated by Con‐TAC versus Con‐Sham and ON/OFF‐Sham versus Con‐Sham, Nox4 expression showed significant increases in ON/OFF‐TAC versus ON/OFF‐Sham groups (Figure 6A). NOX4 is a cardiac reactive oxygen species producer implicated in both metabolic syndromes and pressure overload. 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 Moreover, NOX4 is transcriptionally regulated, 87 , 117 thus protein/activity can be directly inferred from the level of gene expression. Cybb (Figure S10A) encoding the NOX2 isoform is well studied in the context of hyperglycemia and O‐GlcNAc, with work in Lu et al showing regulation of NOX2 post‐transcriptomically through O‐GlcNAcylation of CAMKIIδ which activates NOX2 via phosphorylation. 113 Conversely, the direct regulatory mechanisms of Nox4 expression are still not very well understood; thus, with the literature surrounding NOX4 and it's family members, and our results of exacerbation in the context of O‐GlcNAc memory and TAC, strong opportunities exist within research into Nox4/NOX4 regulation. On the other side of redox mechanisms, Sod2 (mitochondrial superoxide dismutase 2) shows exacerbated decrease in expression (Figure 6B). And Nfe2l2 (nuclear factor erythroid 2‐related factor 2), a central regulator of redox pathways and known O‐GlcNAcylation target, 90 is only upregulated in the Con‐TAC versus Con‐Sham comparison (Figure 6C).

With regards to changes in cardiac metabolism, DEGs as seen in the current study associated with proteins of glucose metabolism, show exacerbated downregulation (Figure 6D and 6E). Downstream, we investigated genes associated with enzymes of the citric acid cycle. Cs, encoding citrate synthase, shows significantly exacerbated downregulation in expression (CI=0.90; Figure 6F); and the majority of DEGs associated with tricarboxylic acid cycle enzymes show significantly exacerbated decrease in expression (Figure S11). Next, we investigated genes associated with proteins of the OXPHOS complexes. In the candidate DEG approach, we see exacerbated decrease in expression (Figure 6G through 6K); and in the pathway‐based approach, we see global decrease gene expression across all OXPHOS complexes in the ON/OFF‐TAC versus Con‐TAC comparison (Figure S12). Finally, with all the changes in cardiac metabolism genes, Ppargc1a expression shows exacerbated decrease in gene expression (Figure S10C). Taking the results of our candidate DEG analysis, we show that changes in redox mechanisms (specifically in NOX4) could drive pathology exacerbation, with opportunities to further research into NOX4's role in cardiac O‐GlcNAcylation; additionally, exacerbated changes in gene expression associated with cardiac metabolism without compensation in mitochondrial homeostasis pathways could represent exacerbated changes because of O‐GlcNAc memory with pressure‐overload and/or drivers of exacerbated cardiac pathology.

With the novel results and strengths of our current study, one caveat that we have reiterated throughout the manuscript is that our initial foray into potential molecular pathways driving of O‐GlcNAc memory are at the gene expression level; despite this caveat, it is encouraging to see the pathways and candidate DEGs from our RNA sequencing reinforce our phenotypic results of pathology exacerbation. Moving forward, the transcriptomic results set the initial blueprint and justification for future molecular and functional studies to elucidate the mechanisms underlying exacerbated cardiac pathology in transiently increased cardiomyocyte O‐GlcNAc upon subsequent pressure overload. Additionally, given that epigenetic mechanisms can drive metabolic memory effects, 18 , 19 , 39 , 40 , 41 future studies are needed to investigate the epigenetic basis of O‐GlcNAc memory. This includes key epigenetic regulators, such as histone methyltransferases like SET/COMPASS and the TETs family of DNA methylation regulation 52 , 118 which provide a potential mechanism for crosstalk via protein O‐GlcNAcylation. Beyond the transcriptomic limitations on mechanistic conclusions, other limitations exist within our current study; however, they also pose opportunities for future studies. Technically, because of limitations of our Vevo 770 system, we could not reliably obtain diastolic function measures; however, with our results on cardiac dysfunction, we recommend researchers studying O‐GlcNAc memory evaluate diastolic function. Additionally, while the measures in our current study show exacerbated cardiac pathology, exercise tolerance testing is needed to further establish a more clinical vignette of CVD and failing hearts. Interestingly, in our model featuring cardiomyocyte‐specific transient O‐GlcNAcylation, we observed distinctive perivascular fibrosis under pressure overload. This finding is notable, as perivascular fibrosis is a characteristic trait of pressure overload hypertrophy at early stages. 119 The presence of fibrosis in the perivascular region, despite the cardiomyocyte‐specific nature of our model, strongly suggests cell–cell crosstalk between cardiomyocytes and other cells via the coronary vasculature, such as fibroblast, macrophages and T‐cells. Moreover, fibrotic signaling such as transforming growth factor‐β can increase extracellular matrix deposition and impair vascular function. Notably, the exacerbated perivascular fibrosis observed under pressure overload present a distinct pathological profile, differing from the interstitial fibrosis we previously identified in our sustained cardiac protein O‐GlcNAc models. 38 Consequently, future studies are warranted to elucidate the specific signaling pathways that link transient O‐GlcNAc induction in cardiomyocytes to the pathogenesis of associated vascular dysfunction.

Nevertheless, the current study demonstrates that the previously transiently increased cardiomyocyte protein O‐GlcNAcylation is sufficient to lead to exacerbation of cardiac pathology in context of pressure overload, and results support the concept of O‐GlcNAc memory as a key player within the cardiac metabolic memory we see in patients with diabetes. While our transcriptomic insights highlight the biological mechanisms underpinning this memory, we acknowledge that these findings are primarily based on transcriptomic analysis and necessitate further experimental validation. Specifically, it is essential to confirm whether DEGs correlate with protein expression levels and whether changes in protein candidates result in functionally significant activity. To advance towards clinical translation, it is imperative to investigate whether the pathological effects observed in our dnOGAh model can be mitigated through O‐GlcNAcylation inhibition such as OGT inhibitors. Furthermore, deeper investigations into O‐GlcNAc biology, such as O‐GlcNAc/phosphorylation interplay using phosphoproteomic approaches are required to evaluate the modification profiles of key proteins involved in cardiac pathology, Future studies need to address several key areas based on our analysis, Nox4‐related reactive oxygen species formation, mitochondria function, oxidative stress capacities, and metabolic changes and oxidative stress capacities of mitochondria, mitochondria function, and metabolic changes. Ultimately, elucidating these pathophysiologic mechanisms remains vital for identifying therapeutic targets and developing successful interventions to ameliorate the increased CVD associated with cardiac metabolic memory.

Sources of Funding

This work was supported by National Institutes of Health [R01 HL133011 and R01 HL167872 to A.R.W., R21 HL152354 to J.C.C. and A.R.W., T32 GM008361, T32 HD071866, and F30 HL172687 to S.F.C., F31 HL154571 to L.A.P., T32 GM008361 to M.S.R., S10OD032422 to UAB Heflin Center for Genomic Science Core Laboratories], and American Heart Association (AHA) [Postdoctoral Fellowship 21POST834132 to C‐M.H., and Predoctoral Fellowship 23PRE1022560 to S.B].

Disclosures

None.

Supporting information

Tables S1–S7

Figures S1–S12

Major Resources Table

JAH3-15-e044089-s001.zip (26.9MB, zip)

ARRIVE Checklist

JAH3-15-e044089-s003.pdf (118.2KB, pdf)

Unedited Blots

JAH3-15-e044089-s002.pdf (318.3KB, pdf)

Acknowledgments

Dr. Michael Crowley of the UAB Heflin Center for Genomic Sciences, Genomics core laboratory. UAB Comparative Pathology Laboratory. Dr. Hind Lal laboratory for access to light microscope for histology slide image capture. Dr. Benjamin Lin for technical assistance with RNA sequencing analyses.

This manuscript was sent to Sakima A. Smith, MD, MPH, Associate Editor, for review by expert referees, editorial decision, and final disposition.

For Sources of Funding and Disclosures, see page 18.

REFERENCES

  • 1. Ahmad FB, Cisewski JA, Anderson RN. Leading causes of death in the US, 2019‐2023. JAMA. 2024;332:957–958. doi: 10.1001/jama.2024.15563 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Organization WH . World Health Statistics 2024: monitoring health for the SDGs, sustainable development goals. Geneva: WHO; 2024. [Google Scholar]
  • 3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843 [DOI] [PubMed] [Google Scholar]
  • 4. CDC . National Diabetes Statistics Report Website. Centers for Disease Control and Prevention; 2024. Accessed February 4, 2025. https://www.cdc.gov/diabetes/php/data‐research/index.html [Google Scholar]
  • 5. Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker‐Smith CM, Bansal N, Beaton AZ, et al. 2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151:e41–e660. doi: 10.1161/CIR.0000000000001303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L, Barker L. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care. 2012;35:1252–1257. doi: 10.2337/dc11-1162 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. McAllister DA, Read SH, Kerssens J, Livingstone S, McGurnaghan S, Jhund P, Petrie J, Sattar N, Fischbacher C, Kristensen SL, et al. Incidence of hospitalization for heart failure and case‐fatality among 3.25 million people with and without diabetes mellitus. Circulation. 2018;138:2774–2786. doi: 10.1161/CIRCULATIONAHA.118.034986 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, Cho K, Wilson PWF, Phillips LS. Diabetes mellitus‐related all‐cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8:e011295. doi: 10.1161/JAHA.118.011295 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Lachin JM, Orchard TJ, Nathan DM; Group DER . Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:39–43. doi: 10.2337/dc13-2116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes C , Complications Trial/Epidemiology of Diabetes I , et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653. doi: 10.1056/NEJMoa052187 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Polak JF, Backlund JY, Cleary PA, Harrington AP, O'Leary DH, Lachin JM, Nathan DM; Group DER . Progression of carotid artery intima‐media thickness during 12 years in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes. 2011;60:607–613. doi: 10.2337/db10-0296 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Pop‐Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, Cleary PA, Lachin JM, Herman WH, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC). Circulation. 2009;119:2886–2893. doi: 10.1161/CIRCULATIONAHA.108.837369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Diabetes C , Complications Trial/Epidemiology of Diabetes I , Complications Study Research G . Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30‐year follow‐up. Diabetes Care. 2016;39:686–693. doi: 10.2337/dc15-1990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Lachin JM, Nathan DM; Group DER . Understanding metabolic memory: the prolonged influence of glycemia during the diabetes control and complications trial (DCCT) on future risks of complications during the study of the epidemiology of diabetes interventions and complications (EDIC). Diabetes Care. 2021;44:2216–2224. doi: 10.2337/dc20-3097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post‐trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404:145–155. doi: 10.1016/S0140-6736(24)00537-3 [DOI] [PubMed] [Google Scholar]
  • 16. Hayward RA, Reaven PD, Emanuele NV, Investigators V. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:978. doi: 10.1056/NEJMc1508386 [DOI] [PubMed] [Google Scholar]
  • 17. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10‐year follow‐up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. doi: 10.1056/NEJMoa0806470 [DOI] [PubMed] [Google Scholar]
  • 18. Chen Z, Miao F, Braffett BH, Lachin JM, Zhang L, Wu X, Roshandel D, Carless M, Li XA, Tompkins JD, et al. DNA methylation mediates development of HbA1c‐associated complications in type 1 diabetes. Nat Metab. 2020;2:744–762. doi: 10.1038/s42255-020-0231-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, et al. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc Natl Acad Sci U S A. 2016;113:E3002–E3011. doi: 10.1073/pnas.1603712113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57:660–671. doi: 10.1007/s00125-014-3171-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Schilling JD, Mann DL. Diabetic cardiomyopathy: bench to bedside. Heart Fail Clin. 2012;8:619–631. doi: 10.1016/j.hfc.2012.06.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Srinivasan VA, Raghavan VA, Parthasarathy S. Biochemical basis and clinical consequences of glucolipotoxicity: a primer. Heart Fail Clin. 2012;8:501–511. doi: 10.1016/j.hfc.2012.06.011 [DOI] [PubMed] [Google Scholar]
  • 23. Taegtmeyer H, Beauloye C, Harmancey R, Hue L. Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol. 2013;305:H1693–H1697. doi: 10.1152/ajpheart.00854.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta. 2010;1801:311–319. doi: 10.1016/j.bbalip.2009.09.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Wende AR, Schell JC, Ha CM, Pepin ME, Khalimonchuk O, Schwertz H, Pereira RO, Brahma MK, Tuinei J, Contreras‐Ferrat A, et al. Maintaining myocardial glucose utilization in diabetic cardiomyopathy accelerates mitochondrial dysfunction. Diabetes. 2020;69:2094–2111. doi: 10.2337/db19-1057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Wende AR, Symons JD, Abel ED. Mechanisms of lipotoxicity in the cardiovascular system. Curr Hypertens Rep. 2012;14:517–531. doi: 10.1007/s11906-012-0307-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Brahma MK, Ha CM, Pepin ME, Mia S, Sun Z, Chatham JC, Habegger KM, Abel ED, Paterson AJ, Young ME, et al. Increased glucose availability attenuates myocardial ketone body utilization. J Am Heart Assoc. 2020;9:e013039. doi: 10.1161/JAHA.119.013039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Prakoso D, Lim SY, Erickson JR, Wallace RS, Lees JG, Tate M, Kiriazis H, Donner DG, Henstridge DC, Davey JR, et al. Fine‐tuning the cardiac O‐GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. Cardiovasc Res. 2022;118:212–225. doi: 10.1093/cvr/cvab043 [DOI] [PubMed] [Google Scholar]
  • 29. Torres CR, Hart GW. Topography and polypeptide distribution of terminal N‐acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O‐linked GlcNAc. J Biol Chem. 1984;259:3308–3317. doi: 10.1016/S0021-9258(17)43295-9 [DOI] [PubMed] [Google Scholar]
  • 30. Hart GW, Housley MP, Slawson C. Cycling of O‐linked beta‐N‐acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446:1017–1022. doi: 10.1038/nature05815 [DOI] [PubMed] [Google Scholar]
  • 31. Chatham JC, Zhang J, Wende AR. Role of O‐linked N‐acetylglucosamine protein modification in cellular (patho)physiology. Physiol Rev. 2021;101:427–493. doi: 10.1152/physrev.00043.2019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Collins HE, Chatham JC. Regulation of cardiac O‐GlcNAcylation: more than just nutrient availability. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165712. doi: 10.1016/j.bbadis.2020.165712 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Wright JN, Collins HE, Wende AR, Chatham JC. O‐GlcNAcylation and cardiovascular disease. Biochem Soc Trans. 2017;45:545–553. doi: 10.1042/BST20160164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Champattanachai V, Marchase RB, Chatham JC. Glucosamine protects neonatal cardiomyocytes from ischemia‐reperfusion injury via increased protein‐associated O‐GlcNAc. Am J Physiol Cell Physiol. 2007;292:C178–C187. doi: 10.1152/ajpcell.00162.2006 [DOI] [PubMed] [Google Scholar]
  • 35. Liu J, Marchase RB, Chatham JC. Increased O‐GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis. Am J Physiol Heart Circ Physiol. 2007;293:H1391–H1399. doi: 10.1152/ajpheart.00285.2007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Ngoh GA, Facundo HT, Hamid T, Dillmann W, Zachara NE, Jones SP. Unique hexosaminidase reduces metabolic survival signal and sensitizes cardiac myocytes to hypoxia/reoxygenation injury. Circ Res. 2009;104:41–49. doi: 10.1161/CIRCRESAHA.108.189431 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Umapathi P, Mesubi OO, Banerjee PS, Abrol N, Wang Q, Luczak ED, Wu Y, Granger JM, Wei AC, Reyes Gaido OE, et al. Excessive O‐GlcNAcylation causes heart failure and sudden death. Circulation. 2021;143:1687–1703. doi: 10.1161/CIRCULATIONAHA.120.051911 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Ha CM, Bakshi S, Brahma MK, Potter LA, Chang SF, Sun Z, Benavides GA, He L, Umbarkar P, Zou L, et al. Sustained increases in cardiomyocyte protein O‐linked beta‐N‐acetylglucosamine levels lead to cardiac hypertrophy and reduced mitochondrial function without systolic contractile impairment. J Am Heart Assoc. 2023;12:e029898. doi: 10.1161/JAHA.123.029898 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. El‐Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205:2409–2417. doi: 10.1084/jem.20081188 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, Calkin AC, Brownlee M, Cooper ME, El‐Osta A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene‐activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009;58:1229–1236. doi: 10.2337/db08-1666 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Okabe J, Orlowski C, Balcerczyk A, Tikellis C, Thomas MC, Cooper ME, El‐Osta A. Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res. 2012;110:1067–1076. doi: 10.1161/CIRCRESAHA.112.266171 [DOI] [PubMed] [Google Scholar]
  • 42. Keating S, El‐Osta A. Epigenetic changes in diabetes. Clin Genet. 2013;84:1–10. doi: 10.1111/cge.12121 [DOI] [PubMed] [Google Scholar]
  • 43. Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart GW, Ripplinger CM, et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O‐linked glycosylation. Nature. 2013;502:372–376. doi: 10.1038/nature12537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Konzman D, Abramowitz LK, Steenackers A, Mukherjee MM, Na HJ, Hanover JA. O‐GlcNAc: regulator of signaling and epigenetics linked to X‐linked intellectual disability. Front Genet. 2020;11:605263. doi: 10.3389/fgene.2020.605263 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Han I, Kudlow JE. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol. 1997;17:2550–2558. doi: 10.1128/MCB.17.5.2550 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, Kudlow JE. O‐GlcNAc modification is an endogenous inhibitor of the proteasome. Cell. 2003;115:715–725. doi: 10.1016/s0092-8674(03)00974-7 [DOI] [PubMed] [Google Scholar]
  • 47. Jackson SP, Tjian R. O‐glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. Cell. 1988;55:125–133. doi: 10.1016/0092-8674(88)90015-3 [DOI] [PubMed] [Google Scholar]
  • 48. Kriaucionis S, Heintz N. The nuclear DNA base 5‐hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324:929–930. doi: 10.1126/science.1169786 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. Conversion of 5‐methylcytosine to 5‐hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930–935. doi: 10.1126/science.1170116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Shi FT, Kim H, Lu W, He Q, Liu D, Goodell MA, Wan M, Songyang Z. Ten‐eleven translocation 1 (Tet1) is regulated by O‐linked N‐acetylglucosamine transferase (Ogt) for target gene repression in mouse embryonic stem cells. J Biol Chem. 2013;288:20776–20784. doi: 10.1074/jbc.M113.460386 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Vella P, Scelfo A, Jammula S, Chiacchiera F, Williams K, Cuomo A, Roberto A, Christensen J, Bonaldi T, Helin K, et al. Tet proteins connect the O‐linked N‐acetylglucosamine transferase Ogt to chromatin in embryonic stem cells. Mol Cell. 2013;49:645–656. doi: 10.1016/j.molcel.2012.12.019 [DOI] [PubMed] [Google Scholar]
  • 52. Zhang Q, Liu X, Gao W, Li P, Hou J, Li J, Wong J. Differential regulation of the ten‐eleven translocation (TET) family of dioxygenases by O‐linked beta‐N‐acetylglucosamine transferase (OGT). J Biol Chem. 2014;289:5986–5996. doi: 10.1074/jbc.M113.524140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Huang P, Ho SR, Wang K, Roessler BC, Zhang F, Hu Y, Bowe DB, Kudlow JE, Paterson AJ. Muscle‐specific overexpression of NCOATGK, splice variant of O‐GlcNAcase, induces skeletal muscle atrophy. Am J Physiol Cell Physiol. 2011;300:C456–C465. doi: 10.1152/ajpcell.00124.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Valencik ML, McDonald JA. Codon optimization markedly improves doxycycline regulated gene expression in the mouse heart. Transgenic Res. 2001;10:269–275. doi: 10.1023/a:1016601928465 [DOI] [PubMed] [Google Scholar]
  • 55. Wust RCI, Houtkooper RH, Auwerx J. Confounding factors from inducible systems for spatiotemporal gene expression regulation. J Cell Biol. 2020;219:219. doi: 10.1083/jcb.202003031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Chatham JC, Young ME. Regulation of myocardial metabolism by the cardiomyocyte circadian clock. J Mol Cell Cardiol. 2013;55:139–146. doi: 10.1016/j.yjmcc.2012.06.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Durgan DJ, Tsai JY, Grenett MH, Pat BM, Ratcliffe WF, Villegas‐Montoya C, Garvey ME, Nagendran J, Dyck JR, Bray MS, et al. Evidence suggesting that the cardiomyocyte circadian clock modulates responsiveness of the heart to hypertrophic stimuli in mice. Chronobiol Int. 2011;28:187–203. doi: 10.3109/07420528.2010.550406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Li MD, Ruan HB, Hughes ME, Lee JS, Singh JP, Jones SP, Nitabach MN, Yang X. O‐GlcNAc signaling entrains the circadian CLOCK by inhibiting BMAL1/CLOCK ubiquitination. Cell Metab. 2013;17:303–310. doi: 10.1016/j.cmet.2012.12.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Wende AR, Young ME, Chatham J, Zhang J, Rajasekaran NS, Darley‐Usmar VM. Redox biology and the interface between bioenergetics, autophagy and circadian control of metabolism. Free Radic Biol Med. 2016;100:94–107. doi: 10.1016/j.freeradbiomed.2016.05.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Froese N, Szaroszyk M, Galuppo P, Visker JR, Werlein C, Korf‐Klingebiel M, Berliner D, Reboll MR, Hamouche R, Gegel S, et al. Hypoxia attenuates pressure overload‐induced heart failure. J Am Heart Assoc. 2024;13:e033553. doi: 10.1161/JAHA.123.033553 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol. 2003;285:H1261–H1269. doi: 10.1152/ajpheart.00108.2003 [DOI] [PubMed] [Google Scholar]
  • 62. Wende AR, Kim J, Holland WL, Wayment BE, O'Neill BT, Tuinei J, Brahma MK, Pepin ME, McCrory MA, Luptak I, et al. Glucose transporter 4‐deficient hearts develop maladaptive hypertrophy in response to physiological or pathological stresses. Am J Physiol Heart Circ Physiol. 2017;313:H1098–H1108. doi: 10.1152/ajpheart.00101.2017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Zou L, Zhang D, Ha CM, Wende AR, Chatham JC. Best practices in assessing cardiac protein O‐GlcNAcylation by immunoblot. Am J Physiol Heart Circ Physiol. 2023;325:H601–H616. doi: 10.1152/ajpheart.00104.2023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, Garcia MU, Di Tommaso P, Nahnsen S. The nf‐core framework for community‐curated bioinformatics pipelines. Nat Biotechnol. 2020;38:276–278. doi: 10.1038/s41587-020-0439-x [DOI] [PubMed] [Google Scholar]
  • 65. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA‐seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Cai H, Chen H, Yi T, Daimon CM, Boyle JP, Peers C, Maudsley S, Martin B. VennPlex—a novel Venn diagram program for comparing and visualizing datasets with differentially regulated datapoints. PLoS One. 2013;8:e53388. doi: 10.1371/journal.pone.0053388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT, Pyysalo S, et al. The STRING database in 2023: protein‐protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638–D646. doi: 10.1093/nar/gkac1000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Luo W, Pant G, Bhavnasi YK, Blanchard SG Jr, Brouwer C. Pathview web: user friendly pathway visualization and data integration. Nucleic Acids Res. 2017;45:W501–W508. doi: 10.1093/nar/gkx372 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28:1947–1951. doi: 10.1002/pro.3715 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Kanehisa M, Furumichi M, Sato Y, Matsuura Y, Ishiguro‐Watanabe M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 2025;53:D672–D677. doi: 10.1093/nar/gkae909 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30. doi: 10.1093/nar/28.1.27 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Rochon J, Gondan M, Kieser M. To test or not to test: preliminary assessment of normality when comparing two independent samples. BMC Med Res Methodol. 2012;12:81. doi: 10.1186/1471-2288-12-81 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Duarte D, Vale N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov. 2022;3:100110. doi: 10.1016/j.crphar.2022.100110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Fischer J. Created in BioRender. 2025. https://BioRender.com/1zp604m.
  • 75. Rahman M. Created in BioRender. 2025. https://BioRender.com/srtx8x4.
  • 76. McLellan MA, Skelly DA, Dona MSI, Squiers GT, Farrugia GE, Gaynor TL, Cohen CD, Pandey R, Diep H, Vinh A, et al. High‐resolution transcriptomic profiling of the heart during chronic stress reveals cellular drivers of cardiac fibrosis and hypertrophy. Circulation. 2020;142:1448–1463. doi: 10.1161/CIRCULATIONAHA.119.045115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016;97:245–262. doi: 10.1016/j.yjmcc.2016.06.001 [DOI] [PubMed] [Google Scholar]
  • 78. Matsiukevich D, Kovacs A, Li T, Kokkonen‐Simon K, Matkovich SJ, Oladipupo SS, Ornitz DM. Characterization of a robust mouse model of heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2023;325:H203–H231. doi: 10.1152/ajpheart.00038.2023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79. Zhu‐Mauldin X, Marsh SA, Zou L, Marchase RB, Chatham JC. Modification of STIM1 by O‐linked N‐acetylglucosamine (O‐GlcNAc) attenuates store‐operated calcium entry in neonatal cardiomyocytes. J Biol Chem. 2012;287:39094–39106. doi: 10.1074/jbc.M112.383778 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Vincendeau E, Wei W, Zhang X, Planchais C, Yu W, Lenden‐Hasse H, Cokelaer T, Pipoli da Fonseca J, Mouquet H, Adams DJ, et al. SHLD1 is dispensable for 53BP1‐dependent V(D)J recombination but critical for productive class switch recombination. Nat Commun. 2022;13:3707. doi: 10.1038/s41467-022-31287-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Hu Y, Suarez J, Fricovsky E, Wang H, Scott BT, Trauger SA, Han W, Hu Y, Oyeleye MO, Dillmann WH. Increased enzymatic O‐GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J Biol Chem. 2009;284:547–555. doi: 10.1074/jbc.M808518200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Bouabout G, Ayme‐Dietrich E, Jacob H, Champy MF, Birling MC, Pavlovic G, Madeira L, Fertak LE, Petit‐Demouliere B, Sorg T, et al. Nox4 genetic inhibition in experimental hypertension and metabolic syndrome. Arch Cardiovasc Dis. 2018;111:41–52. doi: 10.1016/j.acvd.2017.03.011 [DOI] [PubMed] [Google Scholar]
  • 83. Chen L, Zhao M, Li J, Wang Y, Bao Q, Wu S, Deng X, Tang X, Wu W, Liu X. Critical role of X‐box binding protein 1 in NADPH oxidase 4‐triggered cardiac hypertrophy is mediated by receptor interacting protein kinase 1. Cell Cycle. 2017;16:348–359. doi: 10.1080/15384101.2016.1260210 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84. Fan L, Xiao Q, Zhang L, Wang X, Huang Q, Li S, Zhao X, Li Z. CAPE‐pNO(2) attenuates diabetic cardiomyopathy through the NOX4/NF‐kappaB pathway in STZ‐induced diabetic mice. Biomed Pharmacother. 2018;108:1640–1650. doi: 10.1016/j.biopha.2018.10.026 [DOI] [PubMed] [Google Scholar]
  • 85. Gray SP, Shah AM, Smyrnias I. NADPH oxidase 4 and its role in the cardiovascular system. Vasc Biol. 2019;1:H59–H66. doi: 10.1530/VB-19-0014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A. 2010;107:15565–15570. doi: 10.1073/pnas.1002178107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Lassegue B, San Martin A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res. 2012;110:1364–1390. doi: 10.1161/CIRCRESAHA.111.243972 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Nabeebaccus AA, Zoccarato A, Hafstad AD, Santos CX, Aasum E, Brewer AC, Zhang M, Beretta M, Yin X, West JA, et al. Nox4 reprograms cardiac substrate metabolism via protein O‐GlcNAcylation to enhance stress adaptation. JCI Insight. 2017;2:2. doi: 10.1172/jci.insight.96184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Zhang M, Brewer AC, Schroder K, Santos CX, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, et al. NADPH oxidase‐4 mediates protection against chronic load‐induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A. 2010;107:18121–18126. doi: 10.1073/pnas.1009700107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. Tan EP, McGreal SR, Graw S, Tessman R, Koppel SJ, Dhakal P, Zhang Z, Machacek M, Zachara NE, Koestler DC, et al. Sustained O‐GlcNAcylation reprograms mitochondrial function to regulate energy metabolism. J Biol Chem. 2017;292:14940–14962. doi: 10.1074/jbc.M117.797944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. Dorn GW 2nd, Vega RB, Kelly DP. Mitochondrial biogenesis and dynamics in the developing and diseased heart. Genes Dev. 2015;29:1981–1991. doi: 10.1101/gad.269894.115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92. Goto Y, Suzuki K, Ono T, Sasaki M, Toyota T. Development of diabetes in the non‐obese NIDDM rat (GK rat). Adv Exp Med Biol. 1988;246:29–31. doi: 10.1007/978-1-4684-5616-5_4 [DOI] [PubMed] [Google Scholar]
  • 93. Toleman C, Paterson AJ, Whisenhunt TR, Kudlow JE. Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O‐GlcNAcase and HAT activities. J Biol Chem. 2004;279:53665–53673. doi: 10.1074/jbc.M410406200 [DOI] [PubMed] [Google Scholar]
  • 94. Bowe DB, Sadlonova A, Toleman CA, Novak Z, Hu Y, Huang P, Mukherjee S, Whitsett T, Frost AR, Paterson AJ, et al. O‐GlcNAc integrates the proteasome and transcriptome to regulate nuclear hormone receptors. Mol Cell Biol. 2006;26:8539–8550. doi: 10.1128/MCB.01053-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Levine ZG, Potter SC, Joiner CM, Fei GQ, Nabet B, Sonnett M, Zachara NE, Gray NS, Paulo JA, Walker S. Mammalian cell proliferation requires noncatalytic functions of O‐GlcNAc transferase. Proc Natl Acad Sci. 2021;118:e2016778118. doi: 10.1073/pnas.2016778118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96. Ledee D, Smith L, Bruce M, Kajimoto M, Isern N, Portman MA, Olson AK. c‐Myc alters substrate utilization and O‐GlcNAc protein posttranslational modifications without altering cardiac function during early aortic constriction. PLoS One. 2015;10:e0135262. doi: 10.1371/journal.pone.0135262 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97. Matsuno M, Yokoe S, Nagatsuka T, Morihara H, Moriwaki K, Asahi M. O‐GlcNAcylation‐induced GSK‐3beta activation deteriorates pressure overload‐induced heart failure via lack of compensatory cardiac hypertrophy in mice. Front Endocrinol (Lausanne). 2023;14:1122125. doi: 10.3389/fendo.2023.1122125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98. Zhu WZ, Ledee D, Olson AK. Temporal regulation of protein O‐GlcNAc levels during pressure‐overload cardiac hypertrophy. Physiol Rep. 2021;9:e14965. doi: 10.14814/phy2.14965 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99. Zhu WZ, Palazzo T, Zhou M, Ledee D, Olson HM, Pasa‐Tolic L, Olson AK. First comprehensive identification of cardiac proteins with putative increased O‐GlcNAc levels during pressure overload hypertrophy. PLoS One. 2022;17:e0276285. doi: 10.1371/journal.pone.0276285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100. Amrute JM, Luo X, Penna V, Yang S, Yamawaki T, Hayat S, Bredemeyer A, Jung IH, Kadyrov FF, Heo GS, et al. Targeting immune‐fibroblast cell communication in heart failure. Nature. 2024;635:423–433. doi: 10.1038/s41586-024-08008-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101. Feng J, Li Y, Li Y, Yin Q, Li H, Li J, Zhou B, Meng J, Lian H, Wu M, et al. Versican promotes cardiomyocyte proliferation and cardiac repair. Circulation. 2024;149:1004–1015. doi: 10.1161/CIRCULATIONAHA.123.066298 [DOI] [PubMed] [Google Scholar]
  • 102. Tejera‐Munoz A, Cortes M, Rodriguez‐Rodriguez A, Tejedor‐Santamaria L, Marchant V, Rayego‐Mateos S, Gimeno‐Longas MJ, Leask A, Nguyen TQ, Martin M, et al. Ccn2 deletion reduces cardiac dysfunction, oxidative markers, and fibrosis induced by doxorubicin administration in mice. Int J Mol Sci. 2024;25:9617–9631. doi: 10.3390/ijms25179617 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103. Zha Y, Li Y, Ge Z, Wang J, Jiao Y, Zhang J, Zhang S. ADAMTS8 promotes cardiac fibrosis partly through activating EGFR dependent pathway. Front Cardiovasc Med. 2022;9:797137. doi: 10.3389/fcvm.2022.797137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104. Zheng Y, Ye C, Li H, Wang Y, Teng L, Huang Y. Knockdown of TGFB2 attenuates ischemic heart failure by inhibiting apoptosis. Cardiovasc Toxicol. 2025;25:735–749. doi: 10.1007/s12012-025-09974-6 [DOI] [PubMed] [Google Scholar]
  • 105. Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5:S24. doi: 10.1186/1755-1536-5-S1-S24 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K. Role and interaction of connective tissue growth factor with transforming growth factor‐beta in persistent fibrosis: a mouse fibrosis model. J Cell Physiol. 1999;181:153–159. doi: 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K [DOI] [PubMed] [Google Scholar]
  • 107. Ellina O, Chatzigeorgiou A, Kouyanou S, Lymberi M, Mylona‐Karagianni C, Tsouvalas E, Kamper EF. Extracellular matrix‐associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP‐1, CD40, IFN‐gamma) in type 1 diabetes mellitus nephropathy. Clin Chem Lab Med. 2012;50:167–174. doi: 10.1515/cclm.2011.881 [DOI] [PubMed] [Google Scholar]
  • 108. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol. 2009;41:771–783. doi: 10.1016/j.biocel.2008.07.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109. Fan WH, Pech M, Karnovsky MJ. Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro. Eur J Cell Biol. 2000;79:915–923. doi: 10.1078/0171-9335-00122 [DOI] [PubMed] [Google Scholar]
  • 110. Liu S, Shi‐wen X, Abraham DJ, Leask A. CCN2 is required for bleomycin‐induced skin fibrosis in mice. Arthritis Rheum. 2011;63:239–246. doi: 10.1002/art.30074 [DOI] [PubMed] [Google Scholar]
  • 111. Dia M, Gomez L, Thibault H, Tessier N, Leon C, Chouabe C, Ducreux S, Gallo‐Bona N, Tubbs E, Bendridi N, et al. Reduced reticulum‐mitochondria Ca(2+) transfer is an early and reversible trigger of mitochondrial dysfunctions in diabetic cardiomyopathy. Basic Res Cardiol. 2020;115:74. doi: 10.1007/s00395-020-00835-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112. Jozwiak P, Oracz J, Dziedzic A, Szelenberger R, Zyzelewicz D, Bijak M, Krzeslak A. Increased O‐GlcNAcylation by upregulation of mitochondrial O‐GlcNAc transferase (mOGT) inhibits the activity of respiratory chain complexes and controls cellular bioenergetics. Cancers (Basel). 2024;16:1048. doi: 10.3390/cancers16051048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. Lu S, Liao Z, Lu X, Katschinski DM, Mercola M, Chen J, Heller Brown J, Molkentin JD, Bossuyt J, Bers DM. Hyperglycemia acutely increases cytosolic reactive oxygen species via O‐linked GlcNAcylation and CaMKII activation in mouse ventricular myocytes. Circ Res. 2020;126:e80–e96. doi: 10.1161/CIRCRESAHA.119.316288 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114. Yokoe S, Asahi M, Takeda T, Otsu K, Taniguchi N, Miyoshi E, Suzuki K. Inhibition of phospholamban phosphorylation by O‐GlcNAcylation: implications for diabetic cardiomyopathy. Glycobiology. 2010;20:1217–1226. doi: 10.1093/glycob/cwq071 [DOI] [PubMed] [Google Scholar]
  • 115. Zhu WZ, El‐Nachef D, Yang X, Ledee D, Olson AK. O‐GlcNAc transferase promotes compensated cardiac function and protein kinase a O‐GlcNAcylation during early and established pathological hypertrophy from pressure overload. J Am Heart Assoc. 2019;8:e011260. doi: 10.1161/JAHA.118.011260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M, Dillmann WH. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O‐GlcNAcylation. J Biol Chem. 2003;278:44230–44237. doi: 10.1074/jbc.M303810200 [DOI] [PubMed] [Google Scholar]
  • 117. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Forro L, Schlegel W, Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J. 2007;406:105–114. doi: 10.1042/BJ20061903 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118. Deplus R, Delatte B, Schwinn MK, Defrance M, Méndez J, Murphy N, Dawson MA, Volkmar M, Putmans P, Calonne E, et al. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J. 2013;32:645–655. doi: 10.1038/emboj.2012.357 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119. Chalise U, Hale TM. Fibroblasts under pressure: cardiac fibroblast responses to hypertension and antihypertensive therapies. Am J Physiol Heart Circ Physiol. 2024;326:H223–H237. doi: 10.1152/ajpheart.00401.2023 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Tables S1–S7

Figures S1–S12

Major Resources Table

JAH3-15-e044089-s001.zip (26.9MB, zip)

ARRIVE Checklist

JAH3-15-e044089-s003.pdf (118.2KB, pdf)

Unedited Blots

JAH3-15-e044089-s002.pdf (318.3KB, pdf)

Data Availability Statement

Further materials and reagents used in experiments are found in the Supplemental Material: Major Resources Table. The data to support findings of this study are accessible upon request from the corresponding author. Files associated with the RNA‐sequencing for this study are found on NCBI GEO repository (GSE298401).


Articles from Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease are provided here courtesy of Wiley

RESOURCES